Table 2.

Univariable and multivariable analyses (Cox regression)

VariableProgression
UnivariableMultivariable 1 (n = 512)Multivariable 2 (n = 414)
Age    
 HR 1.00   
 95% CI 0.99-1.01   
P .99   
Male sex    
 HR 1.28 1.24 1.25 
 95% CI 0.92-1.77 0.90-1.72 0.87-1.79 
P .14 .19 .23 
Extranodal disease    
 HR 0.83 0.95 1.02 
 95% CI 0.56-1.23 0.64-1.42 0.65-1.58 
P .35 .81 .95 
Grade 3A or 3 NOS    
 HR 0.91   
 95% CI 0.50-1.64   
P .75   
Pretreatment size    
 HR 1.06   
 95% CI 0.95-1.17   
P .29   
Stage II disease    
 HR 2.34 2.26 2.11 
 95% CI 1.66-3.30 1.63-3.19 1.44-3.10 
P <.0001 <.0001 .0001 
FLIPI score    
 HR 1.04 1.05 1.10 
 95% CI 0.80-1.37 0.80-1.38 0.81-1.50 
P .75 .71 .53 
BCL2+ (n = 414)    
 HR 1.64  1.63 
 95% CI 1.09-2.46  1.07-2.47 
P .02  .02 
VariableProgression
UnivariableMultivariable 1 (n = 512)Multivariable 2 (n = 414)
Age    
 HR 1.00   
 95% CI 0.99-1.01   
P .99   
Male sex    
 HR 1.28 1.24 1.25 
 95% CI 0.92-1.77 0.90-1.72 0.87-1.79 
P .14 .19 .23 
Extranodal disease    
 HR 0.83 0.95 1.02 
 95% CI 0.56-1.23 0.64-1.42 0.65-1.58 
P .35 .81 .95 
Grade 3A or 3 NOS    
 HR 0.91   
 95% CI 0.50-1.64   
P .75   
Pretreatment size    
 HR 1.06   
 95% CI 0.95-1.17   
P .29   
Stage II disease    
 HR 2.34 2.26 2.11 
 95% CI 1.66-3.30 1.63-3.19 1.44-3.10 
P <.0001 <.0001 .0001 
FLIPI score    
 HR 1.04 1.05 1.10 
 95% CI 0.80-1.37 0.80-1.38 0.81-1.50 
P .75 .71 .53 
BCL2+ (n = 414)    
 HR 1.64  1.63 
 95% CI 1.09-2.46  1.07-2.47 
P .02  .02 

Analyses of pretreatment patient characteristics associated with progression after primary RT.

NOS, not otherwise specified.

Close Modal

or Create an Account

Close Modal
Close Modal